Highlights on Advancing Frontiers in Tissue Engineering
Rattachement africain : us, ca, tr, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The field of tissue engineering continues to advance, sometimes in exponential leaps forward, but also sometimes at a rate that does not fulfill the promise that the field imagined a few decades ago. This review is in part a catalog of success in an effort to inform the process of innovation. Tissue engineering has recruited new technologies and developed new methods for engineering tissue constructs that can be used to mitigate or model disease states for study. Key to this antecedent statement is that the scientific effort must be anchored in the needs of a disease state and be working toward a functional product in regenerative medicine. It is this focus on the wildly important ideas coupled with partnered research efforts within both academia and industry that have shown most translational potential. The field continues to thrive and among the most important recent developments are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies that warrant special attention. Developments in the aforementioned areas as well as future directions are highlighted in this article. Although several early efforts have not come to fruition, there are good examples of commercial profitability that merit continued investment in tissue engineering. Impact statement Tissue engineering led to the development of new methods for regenerative medicine and disease models. Among the most important recent developments in tissue engineering are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies. These technologies and an understanding of them will have impact on the success of tissue engineering and its translation to regenerative medicine. Continued investment in tissue engineering will yield products and therapeutics, with both commercial importance and simultaneous disease mitigation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Highlights on Advancing Frontiers in Tissue Engineering
- Date Crossref
- 01/06/2022
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
Samueli Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Michigan State University pays non établi dans la noticeUniversité ou école supérieure
-
University of Toronto pays non établi dans la noticeUniversité ou école supérieure
-
Istanbul University-Cerrahpaşa pays non établi dans la noticeUniversité ou école supérieure
-
University of Sheffield pays non établi dans la noticeUniversité ou école supérieure
-
Imperial College London pays non établi dans la noticeUniversité ou école supérieure
-
VA Greater Los Angeles Healthcare System pays non établi dans la noticeÉtablissement de santé
-
University of Leeds Academic Department of Trauma and Orthopaedics pays non établi dans la noticeUniversité ou école supérieure
-
Alfred I. duPont Hospital for Children pays non établi dans la noticeÉtablissement de santé
-
Henry Samueli School of Engineering Department of Bioengineering pays non établi dans la noticeUniversité ou école supérieure
-
College of Engineering Department of Biomedical Engineering pays non établi dans la noticeUniversité ou école supérieure
University of California, Samueli Institute et Michigan State University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.